{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:25:23Z","timestamp":1792157123283,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Advancement of Military Medicine, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The majority of active duty service women (ADS) are young, have access to healthcare, and meet fitness standards set by the U.S. military, suggesting that ADS represent a healthy population at low risk of cancer. Breast cancer is, however, the most common cancer in ADS and may have a significant effect on troop readiness with lengthy absence during treatment and inability to return to duty after the treatment. The identification of unaffected ADS who carry germline mutations in cancer predisposition genes (\u201cprevivors\u201d) would provide the opportunity to prevent or detect cancer at an early stage, thus minimizing effects on troop readiness. In this study, we determined (1) how many high-risk ADS without cancer pursued genetic testing, (2) how many previvors employed risk-reducing strategies, and (3) the number of undiagnosed previvors within an ADS population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Clinical Breast Care Project (protocol WRNMMC IRB #20704) database of the Murtha Cancer Center\/Walter Reed National Military Medical Center was queried to identify all ADS with no current or previous history of cancer. Classification as high genetic risk was calculated using National Comprehensive Cancer Network 2019 guidelines for genetic testing for breast, ovary, colon, and gastric cancer. The history of clinical genetic testing and risk-reducing strategies was extracted from the database. Genomic DNA from ADS with blood specimens available for research purposes were subjected to next-generation sequencing technologies using a cancer predisposition gene panel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 336 cancer-free ADS enrolled in the Clinical Breast Care Project, 77 had a family history that met National Comprehensive Cancer Network criteria for genetic testing for BRCA1\/2 and 2 had a family history of colon cancer meeting the criteria for genetic testing for Lynch syndrome. Of the 28 (35%) high-risk women who underwent clinical genetic testing, 11 had pathogenic mutations in the breast cancer genes BRCA1 (n\u2009=\u20095), BRCA2 (n\u2009=\u20095), or CHEK2 (n\u2009=\u20091). Five of the six ADS who had a relative with a known pathogenic mutation were carriers of the tested mutation. All of the women who had pathogenic mutations detected through clinical genetic testing underwent prophylactic double mastectomy, and three also had risk-reducing salpingo-oophorectomy. Two (6%) of the 33 high-risk ADS tested only in the research setting had a family history of breast\/ovarian cancer and carried pathogenic mutations: one carried a BRCA2 mutation, whereas the other carried a mutation in the colon cancer predisposition gene PMS2. No mutations were detected in the 177 low-risk women tested in the research setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Within this unaffected cohort of ADS, 23% were classified as high risk. Although all of the previvors engaged in risk-reduction strategies, only one-third of the high-risk women sought genetic testing. These data suggest that detailed family histories of cancer should be collected in ADS and genetic testing should be encouraged in those at high risk. The identification of previvors and concomitant use of risk-reduction strategies may improve health in the ADS and optimize military readiness by decreasing cancer incidence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/milmed\/usaa485","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T04:31:04Z","timestamp":1607315464000},"source":"Crossref","is-referenced-by-count":1,"title":["Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness"],"prefix":"10.1093","author":[{"given":"Leann A","family":"Lovejoy","sequence":"first","affiliation":[{"name":"Clinical Breast Care Project, Chan Soon-Shiong Institute for Molecular Medicine at Windber, Windber, PA 15963, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clesson E","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA"},{"name":"Murtha Cancer Center\/Research Program, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, MD 20889, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig D","family":"Shriver","sequence":"additional","affiliation":[{"name":"Murtha Cancer Center\/Research Program, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, MD 20889, USA"},{"name":"Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E","family":"Ellsworth","sequence":"additional","affiliation":[{"name":"Murtha Cancer Center\/Research Program, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, MD 20889, USA"},{"name":"Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military Medicine, Windber, PA 15963, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"2020120621200327200_R1","article-title":"Demographics: Profile of the Military Community","volume-title":"Department of Defense","author":"Department of Defense","year":"2018"},{"issue":"8","key":"2020120621200327200_R2","first-page":"789","article-title":"Cancer incidence in the U.S. Air Force: 1989-2002","volume":"77","author":"Yamane","year":"2006","journal-title":"Aviat Space Environ Med"},{"issue":"9","key":"2020120621200327200_R3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.7205\/MILMED.169.9.707","article-title":"Neoplasms in the Navy, 1998-2000: a descriptive analysis of the physical evaluation board database","volume":"169","author":"Ajene","year":"2004","journal-title":"Mil Med"},{"issue":"6","key":"2020120621200327200_R4","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1158\/1055-9965.EPI-09-0041","article-title":"Cancer incidence in the U.S. Military population: comparison with rates from the SEER program","volume":"18","author":"Zhu","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"2020120621200327200_R5","first-page":"25","article-title":"Incident diagnoses of breast cancer, active component service women, U.S. Armed Forces, 2000-2012","volume":"20","author":"Armed Forces Health Surveillance C","year":"2013","journal-title":"MSMR"},{"issue":"4 Suppl 1","key":"2020120621200327200_R6","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1097\/MLR.0000000000000299","article-title":"Women with breast cancer in the Veterans Health Administration: demographics, breast cancer characteristics, and trends","volume":"53","author":"Colonna","year":"2015","journal-title":"Med Care"},{"issue":"11-12","key":"2020120621200327200_R7","doi-asserted-by":"crossref","first-page":"e500","DOI":"10.1093\/milmed\/usy052","article-title":"Costs for breast cancer care in the military health system: an analysis by benefit type and care source","volume":"183","author":"Eaglehouse","year":"2018","journal-title":"Mil Med"},{"key":"2020120621200327200_R8","article-title":"Breaking ranks, lab offers test to assess risk of breast cancer","volume-title":"N Y Times","author":"Kolata","year":"1996"},{"issue":"12","key":"2020120621200327200_R9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120524","article-title":"BRCA mutations and breast cancer prevention","volume":"10","author":"Kotsopoulos","year":"2018","journal-title":"Cancers"},{"key":"2020120621200327200_R10","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): genetic\/familial high-risk assessment: breast, ovarian, and pancreatic","volume":"1.2020","author":"National Comprehensive Cancer Network","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"2020120621200327200_R11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"7","key":"2020120621200327200_R12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol"},{"issue":"8","key":"2020120621200327200_R13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/jnci\/djz008","article-title":"Trends in BRCA test utilization in an integrated health system, 2005-2015","volume":"111","author":"Knerr","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2020120621200327200_R14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","article-title":"Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers","volume":"148","author":"Chai","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2020120621200327200_R15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.32572","article-title":"Clinical utility of hereditary cancer panel testing: impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations","volume":"126","author":"Vysotskaia","year":"2020","journal-title":"Cancer"},{"issue":"13 Suppl","key":"2020120621200327200_R16","article-title":"Population-based breast cancer risk estimates associated with cancer predisposition gene mutations from 32,298 breast cancer patients and 31,869 matched unaffected controls from the CARRIERS study","volume":"79","author":"Couch","year":"2019","journal-title":"Cancer Res"},{"key":"2020120621200327200_R17","article-title":"Genetic\/familial high-risk assessment: breast and ovarian cancer","volume":"3.2019","author":"National Comprehensive Cancer Network","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2020120621200327200_R18","article-title":"Genetic\/familal high-risk assessment: colorectal","volume":"3.2019","author":"National Comprehensive Cancer Network","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2020120621200327200_R19","article-title":"Gastric cancer","volume":"2.2020","author":"National Comprehensive Cancer Network","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2020120621200327200_R20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","article-title":"International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation","volume":"121","author":"Metcalfe","year":"2019","journal-title":"Br J Cancer"},{"issue":"69","key":"2020120621200327200_R21","doi-asserted-by":"crossref","first-page":"33062","DOI":"10.18632\/oncotarget.25995","article-title":"Population based germline testing for primary cancer prevention","volume":"9","author":"Manchanda","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"2020120621200327200_R22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jamcollsurg.2008.12.001","article-title":"Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease","volume":"208","author":"Gnerlich","year":"2009","journal-title":"J Am Coll Surg"},{"issue":"5","key":"2020120621200327200_R23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1200\/JCO.1994.12.5.888","article-title":"Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer","volume":"12","author":"Nixon","year":"1994","journal-title":"J Clin Oncol"},{"issue":"21","key":"2020120621200327200_R24","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"2020120621200327200_R25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jama.2014.12483","article-title":"Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award","volume":"312","author":"King","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"2020120621200327200_R26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2013.50.9257","article-title":"American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers","volume":"32","author":"Lu","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020120621200327200_R27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/tbj.13722","article-title":"Importance of family history and indications for genetic testing","volume":"26","author":"Wood","year":"2020","journal-title":"Breast J"},{"issue":"12","key":"2020120621200327200_R28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/gim.2016.29","article-title":"Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations","volume":"18","author":"D\u2019Andrea","year":"2016","journal-title":"Genet Med"},{"issue":"2","key":"2020120621200327200_R29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1017\/S0266462319003519","article-title":"Canadian cost-effect-iveness model of BRCA-driven surgical prevention of breast\/ovarian cancers compared to treatment if cancer develops","volume":"36","author":"Hurry","year":"2020","journal-title":"Int J Technol Assess Health Care"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/advance-article-pdf\/doi\/10.1093\/milmed\/usaa485\/34383080\/usaa485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/advance-article-pdf\/doi\/10.1093\/milmed\/usaa485\/34383080\/usaa485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T04:31:16Z","timestamp":1607315476000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/advance-article\/doi\/10.1093\/milmed\/usaa485\/5988992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaa485","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"article-number":"usaa485"}}